LXEO
Price
$3.15Alerts
Change
+$0.20 (+6.78%)
Updated
Nov 20, 11:50 AM (EDT)
Capitalization
237.23M
Intraday BUY SELL Signals
SLDB
Price
$6.38Alerts
Change
-$0.06 (-0.93%)
Updated
Nov 20, 11:56 AM (EDT)
Capitalization
706.61M
116 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

LXEO vs SLDB

LXEO vs SLDB Comparison Chart in %
loading
loading
View a ticker or compare two or three
A.I.Advisor
Oct 28, 2026

Which Stock Would AI Choose? Lexeo Therapeutics (LXEO) vs. Solid Biosciences (SLDB) Stock Comparison

Key Takeaways

  • Both LXEO and SLDB are clinical-stage genetic medicine companies, but they differ in pipeline breadth, cash position, and near-term catalysts.
  • Solid Biosciences carries a more diversified neuromuscular and cardiac pipeline, while Lexeo Therapeutics is more narrowly focused on genetically defined cardiovascular diseases.
  • SLDB reported a larger recent net loss but held roughly $377.7 million in cash at mid-2026 versus about $234.2 million for LXEO, a factor in relative balance-sheet stability.
  • Both companies have overlapping interest in Friedreich's ataxia (a rare inherited disease affecting the nervous system and heart), creating a direct competitive angle for investors.
  • Analyst sentiment appears comparatively stronger on SLDB in recent coverage, while LXEO's near-term story centers on pivotal-trial execution and regulatory milestones.
  • For more detail on these tickers, visit LXEO Major News and LXEO Today's Price Move, as well as SLDB Major News and SLDB Today's Price Move.
  • For AI-driven market insights across thousands of tickers, explore Trending AI Robots.

Introduction

Investors evaluating the gene therapy segment often face a choice between focused, single-franchise developers and broader, multi-program platforms. Lexeo Therapeutics (LXEO) and Solid Biosciences (SLDB) exemplify this divide. Both are clinical-stage companies pursuing genetic medicines for serious cardiac and neuromuscular conditions, and both operate pre-revenue, meaning their valuations hinge on trial data, regulatory progress, and cash runway rather than current sales. This stock comparison is relevant to traders tracking biotech momentum and to long-term investors weighing pipeline depth, financial stability, and catalyst timing. The sections below assess each company's recent performance and market positioning without favoring either by wording.

LXEO Overview and Recent Performance

Lexeo Therapeutics is a clinical-stage genetic medicine company developing treatments for genetically defined cardiovascular diseases. Its lead program, LX2006, targets Friedreich's ataxia cardiomyopathy, a heart complication of the rare inherited disease Friedreich's ataxia. In recent weeks, the company has focused on executing its pivotal SUNRISE-FA 2 trial, which began enrolling patients in mid-2026, with topline data anticipated in the second half of 2027. Lexeo also advanced LX2020, a candidate for PKP2 arrhythmogenic cardiomyopathy, for which the U.S. Food and Drug Administration (FDA) granted RMAT (Regenerative Medicine Advanced Therapy) designation based on interim clinical data.

Financially, Lexeo reported a net loss of about $25.9 million in its most recent quarter, with research and development spending rising as trials progressed. The company held approximately $234.2 million in cash and marketable securities as of June 30, 2026, which management expects to fund operations into 2028. Recent stock behavior has reflected a mix of enthusiasm around the RMAT designation and caution tied to the long timeline before potential commercialization. A potential BLA (Biologics License Application) submission under the accelerated approval pathway is targeted for the first half of 2028, underscoring the multi-year horizon embedded in this investment case.

SLDB Overview and Recent Performance

Solid Biosciences is a precision genetic medicine company advancing a portfolio of gene therapy candidates for rare neuromuscular and cardiac diseases. Its lead asset, SGT-003, is an investigational gene therapy for Duchenne muscular dystrophy (DMD, a progressive muscle-wasting disease), supported by positive interim Phase 1/2 data and an ongoing Phase 3 confirmatory trial. The company has also advanced SGT-212 for Friedreich's ataxia, a direct overlap with Lexeo's LX2006 program, and recently received Orphan designation from the European Commission for SGT-212.

In recent market activity, Solid reported a net loss of approximately $54.8 million for its latest quarter, reflecting higher clinical and manufacturing costs. Its balance sheet, however, was comparatively stronger, with about $377.7 million in cash and available-for-sale securities as of June 30, 2026, and no outstanding debt. This funding is expected to support operations into mid-2028. A planned FDA meeting in late 2026 to discuss a potential accelerated approval pathway for SGT-003 represents a nearer-term catalyst, and recent analyst coverage has leaned positive on the stock's pipeline breadth and cash position.

Trending AI Robots

Tickeron maintains hundreds of AI trading bots that collectively trade thousands of different tickers, each built around distinct trading styles, strategies, timeframes, performance records, and target ticker lists. Rather than presenting every available bot, Tickeron curates a focused selection known as Trending AI Robots, which highlights the bots best suited to current market conditions. Because no single strategy fits every environment, this curated section helps traders filter for approaches aligned with prevailing momentum, volatility, and trend characteristics across sectors such as biotechnology. For readers following names like LXEO and SLDB, reviewing the trending selection can add a data-driven layer to discretionary analysis. Explore the full list at Trending AI Robots.

Head-to-Head Comparison

The clearest contrast between these two stocks is pipeline strategy. Solid Biosciences operates a broader platform spanning DMD, Friedreich's ataxia, and additional cardiac indications, while Lexeo concentrates on a tighter set of cardiac genetic medicines. This breadth gives SLDB multiple shots on goal but also higher quarterly operating losses; LXEO's focus lowers expense intensity but concentrates risk in fewer programs. Both companies are pre-revenue, so neither offers current profitability as a valuation anchor.

On growth drivers, SLDB's SGT-003 is further along commercially, with a Phase 3 trial underway and a regulatory meeting expected in late 2026, whereas LXEO's pivotal SUNRISE-FA 2 data is not expected until 2027. In terms of financial stability, Solid's larger cash balance and debt-free position provide a longer runway relative to Lexeo's more modest reserve, though both expect funding into 2028. Sector exposure is similar, as each sits within high-risk, high-reward rare-disease gene therapy. Market sentiment in recent weeks has been comparatively more constructive on SLDB, while LXEO's relative performance has been more muted, reflecting its longer catalyst timeline and narrower pipeline.

Tickeron AI Verdict

Based on observable factors, Tickeron's AI framework would likely assign a modest edge to Solid Biosciences (SLDB) over Lexeo Therapeutics (LXEO) in the current environment. SLDB's combination of a broader pipeline, a nearer-term regulatory catalyst in late 2026, a larger cash reserve, and comparatively stronger recent analyst sentiment supports more consistent trend and stability signals. LXEO's focused execution and the RMAT designation for LX2020 are notable positives, but its primary data readout sits further out, and its smaller cash base introduces greater sensitivity to financing conditions. This assessment reflects probabilistic, signal-driven positioning rather than a definitive outcome, and either stock could re-rate quickly on clinical or regulatory news.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

VS
LXEO vs. SLDB commentary
Nov 20, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LXEO is a Hold and SLDB is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for LXEO with price predictions
Nov 19, 2026

LXEO's RSI Oscillator climbs out of oversold territory

The RSI Oscillator for LXEO moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 15 similar instances when the indicator left oversold territory. In 14 of the 15 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Momentum Indicator moved above the 0 level on November 19, 2026. You may want to consider a long position or call options on LXEO as a result. In 39 of 48 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

The Moving Average Convergence Divergence (MACD) for LXEO just turned positive on October 20, 2026. Looking at past instances where LXEO's MACD turned positive, the stock continued to rise in 27 of 31 cases over the following month. The odds of a continued upward trend are 87%.

Following a +5.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where LXEO advanced for three days, in 152 of 180 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

The Aroon Indicator entered an Uptrend today. In 93 of 98 cases where LXEO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LXEO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. LXEO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.009) is normal, around the industry mean (3.596). P/E Ratio (-3.284) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LXEO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for SLDB with price predictions
Nov 19, 2026

Momentum Indicator for SLDB turns positive, indicating new upward trend

SLDB saw its Momentum Indicator move above the 0 level on November 19, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 69 similar instances where the indicator turned positive. In 59 of the 69 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SLDB's RSI Indicator exited the oversold zone, 32 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for SLDB just turned positive on October 21, 2026. Looking at past instances where SLDB's MACD turned positive, the stock continued to rise in 35 of 42 cases over the following month. The odds of a continued upward trend are 83%.

Following a +3.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLDB advanced for three days, in 201 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

The Aroon Indicator entered an Uptrend today. In 142 of 171 cases where SLDB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.

Bearish Trend Analysis

SLDB moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

The 50-day moving average for SLDB moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLDB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

SLDB broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.889) is normal, around the industry mean (3.596). P/E Ratio (-3.487) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 54 (best 1 - 100 worst), indicating steady price growth. SLDB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLDB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
SLDB: Fundamental Ratings
SLDB
OUTLOOK RATING
1..100
34
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
54
P/E GROWTH RATING
1..100
22
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
LXEOSLDB
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
78%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
73%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
86%
MACD
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 17 days ago
84%
Bullish Trend 1 day ago
79%
Declines
ODDS (%)
Bearish Trend 8 days ago
90%
Bearish Trend 4 days ago
89%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
83%
COMPARISON
Comparison
Nov 20, 2026
Stock price -- (LXEO: $2.95 vs. SLDB: $6.44)
Brand notoriety: LXEO and SLDB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LXEO: 59% vs. SLDB: 119%
Market capitalization -- LXEO: $237.23M vs. SLDB: $706.61M
LXEO [@Biotechnology] is valued at $237.23M. SLDB’s [@Biotechnology] market capitalization is $706.61M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LXEO’s FA Score shows that 1 FA rating(s) are green while SLDB’s FA Score has 2 green FA rating(s).

  • LXEO’s FA Score: 1 green, 4 red.
  • SLDB’s FA Score: 2 green, 3 red.
According to our system of comparison, SLDB is a better buy in the long-term than LXEO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LXEO’s TA Score shows that 6 TA indicator(s) are bullish while SLDB’s TA Score has 6 bullish TA indicator(s).

  • LXEO’s TA Score: 6 bullish, 1 bearish.
  • SLDB’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, LXEO is a better buy in the short-term than SLDB.

Price Growth

LXEO (@Biotechnology) experienced а +1.37% price change this week, while SLDB (@Biotechnology) price change was -8.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.27%. For the same industry, the average monthly price growth was -14.83%, and the average quarterly price growth was -25.31%.

Reported Earning Dates

SLDB is expected to report earnings on Mar 16, 2027.

Industries' Descriptions

@Biotechnology (-9.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

LXEO and

Correlation & Price change

A.I.dvisor indicates that over the last year, LXEO has been loosely correlated with PRME. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if LXEO jumps, then PRME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LXEO
1D Price
Change %
LXEO100%
N/A
PRME - LXEO
51%
Loosely correlated
+0.52%
SLDB - LXEO
50%
Loosely correlated
+1.42%
IMVT - LXEO
50%
Loosely correlated
-1.96%
RCKT - LXEO
48%
Loosely correlated
N/A
STOK - LXEO
48%
Loosely correlated
+0.90%
More

SLDB and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLDB has been loosely correlated with EDIT. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if SLDB jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLDB
1D Price
Change %
SLDB100%
+1.42%
EDIT - SLDB
62%
Loosely correlated
-3.39%
RCKT - SLDB
54%
Loosely correlated
N/A
BEAM - SLDB
54%
Loosely correlated
-0.33%
DYN - SLDB
54%
Loosely correlated
+1.01%
FDMT - SLDB
54%
Loosely correlated
+2.49%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CGCB25.29N/A
N/A
Capital Group Core Bond ETF (CGCB)
BUFT25.99-0.21
-0.79%
FT Vest Buffered Allocation Defensive ETF (BUFT)
ESMV31.06-0.50
-1.58%
iShares ESG Optimized MSCI USA Min Vol Factor ETF (ESMV)
DVLU36.83-0.65
-1.75%
First Trust Dorsey Wright Momentum & Value ETF (DVLU)
XSVM64.56-1.38
-2.09%
Invesco S&P SmallCap Value with Momentum ETF (XSVM)